(195 days)
Not Found
No
The description focuses on a standard electrochemical method for glucose measurement and does not mention any AI or ML components.
Yes
This device is intended to aid in monitoring the effectiveness of a diabetes control program, which is a therapeutic purpose.
No
The text explicitly states: "It is not intended for the diagnosis of or screening for diabetes mellitus". It is instead intended for "monitoring the effectiveness of diabetes control program."
No
The device description explicitly states the system consists of a meter and test strips, which are hardware components, and describes an electrochemical method utilizing these components.
Yes, based on the provided information, the Prodigy Blood Glucose Test System is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative measurement of glucose in whole blood taken from the finger." This involves testing a biological sample (blood) outside of the body to provide information about a person's health status (glucose levels related to diabetes).
- Device Description: The description details a "system utilizes an electrochemical method-based meter and dry reagent biosensor (test strips) for blood glucose testing." This describes the components and method used to perform the in vitro test.
- Anatomical Site: The mention of "whole blood taken from the finger" and "capillary whole blood from the fingertip" confirms that the test is performed on a biological sample obtained from the patient.
The definition of an IVD generally includes devices intended for use in the examination of specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The Prodigy Blood Glucose Test System clearly fits this description as it measures glucose in blood for monitoring diabetes control.
N/A
Intended Use / Indications for Use
The Prodigy Blood Glucose Test System is intended for use in the quantitative measurement of glucose in whole blood taken from the finger. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and are not intended for use on neonates.
The Prodiqy Blood Glucose Test System is intended to be used for the quantitative measurement of glucose in capillary whole blood from the fingertip. It is intended for use by people with diabetes mellitus at home (Over -the-Counter) as an aid in monitoring the effectiveness of diabetes control program. The Prodigy blood glucose test system can also be used at clinical sites by nurses or professional people to test patient's glucose level in whole blood. It is not intended for the diagnosis of or screening for diabetes mellitus, and not intended for use on neonates.
The Prodigy meter is to be used with the Prodigy Blood Glucose Test Strip, and the Prodigy Glucose Control Solutions.
Product codes (comma separated list FDA assigned to the subject device)
NBW, CGA, JJX
Device Description
The Prodigy glucose test system consists of a meter and test strips. The system utilizes an electrochemical method-based meter and dry reagent biosensor (test strips) for blood glucose testing. The size of the current is proportional to the amount of glucose present in the sample, providing a quantitative measurement of glucose in fresh whole blood and control solutions.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
finger, fingertip
Indicated Patient Age Range
not intended for use on neonates.
Intended User / Care Setting
healthcare professionals and people with diabetes mellitus at home
people with diabetes mellitus at home (Over -the-Counter), clinical sites by nurses or professional people
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The results of clinical and non-clinical testing indicate that the new device is as safe and effective as the predicate.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
510 (k) Summary
General Information Establishment
JUL - 6 2006
Applicant: DIAGNOSTIC DEVICES, INC.Inc. Address: 8935 NW 27th street, Miami, FL 33172. U.S.A. Registration Number: 3004622211 Contact Person: Rick Admani Abulhaj Director of Finance and Operation TEL: 1-800-2432636 FAX: 1-305-6205220 Data submitted: December 21, 2005
Device
Proprietary /Trade Name: Prodigy Blood Glucose Test System Common Name: Blood Glucose Test System Classification Name: SYSTEM, TEST BLOOD GLUCOSE, Class II Regulation sections: 21 CFR § 862.13485, Glucose Test System 21 CFR § 862.1660, Quality Control Material, assayed and Unassayed. Classification: Class II (Glucose Test System) Class I -reserved (Quality Control Matcrial) Product code: NBW, CGA (Glucose Test System) JJX (Quality Control Material) Panel: 75 (Clinical Chemistry)-Glucose Test system and Quality Control Material
Safety and Effective Information
Predicate Device:
Claim of Substantial Equivalence (SE) is made to TaiDoc Technology Corporation. K042005, Achtung TD-4207/ Clever Chek TD-4209/ Clever Chek TD-4222 Glucose Test Systems.
1
Indications for Use:
The Prodigy Blood Glucose Test System is intended for use in the quantitative measurement of glucose in whole blood taken from the finger. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and are not intended for use on neonates.
Device Description:
The Prodigy glucose test system consists of a meter and test strips. The system utilizes an electrochemical method-based meter and dry reagent biosensor (test strips) for blood glucose testing. The size of the current is proportional to the amount of glucose present in the sample, providing a quantitative measurement of glucose in fresh whole blood and control solutions.
Safety and Effectiveness, comparison to predicate device:
The results of clinical and non-clinical testing indicate that the new device is as safe and effective as the predicate.
| Similarities | ||
|---|---|---|
| Item | New Device: Prodigy | Predicate K042005 |
| Enzyme | Glucose oxidase | Glucose oxidase |
| Test range | 20-600 mg/dL | 20-600 mg/dL |
| Test strip calibration | Code strip | Code strip |
| Sample volume | 1.8-2.5 uL | 1.8-2.5 uL |
| Test time | 10 sec. | 10 sec. |
| Operating condition | 10 - 40°C | 10 - 40°C |
| and humidity range | 10 - 90 % R.H. | 10 - 90 % R.H. |
| Storage/Transportation | ||
| condition | -20 - 70°C | |
| 5 - 95 % R.H. | -20 - 70°C | |
| 5 - 95 % R.H. | ||
| Difference | ||
| Item | New Device: Prodigy | Predicate K042005 |
| Size | 88mm X 62mm X 22mm | 80mm X 60mm X 20mm |
| Weight | 26.5 g | 48.79 g |
Substantial Equivalence Chart:
2
Conclusion
After analyzing clinical and non-clinical testing data, it is the conclusion of Diagnostic Devices, Inc.,Inc. that the prodigy blood Glucose Test system is as safe and effective as the predicate device, has few technological differences, and has no new indications for use, thus rendering it substantially equivalence to the predicate device.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with its wings spread, and three horizontal bars below the eagle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Diagnostic Devices Inc. c/o Mr. Daniel Kamm, P.E. Regulatory Engineer Kamm& Associates PO Box 7007 Deerfield IL 60015
Re: K053593
Trade/Device Name: Prodigy Blood Glucose Test System Regulation Number: 21 CFR§ 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW, CGA, JJX Dated: June 12, 2006 Received: June 14, 2006
Dear Mr. Kamm:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the udictions for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisiops of the I ( The general controls provisions of the Act include requirements for annual registration, inte rece devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
JUL - 6 2006
If your device is classified (see above) into cither class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your revire, can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition FDA may publish further announcements concerning your device in the Federal Degister.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including, but not limited to: registration and Isiting (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing pratice requirements as set forth in the quality systems (QS) regulation (2) CFR Part 820),
4
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, pervoits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tloin the (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Alberto Gutierrez, Ph.D.
Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number: K053593
Device Name: Prodigy Blood Glucose Test System
Indications For Use:
The Prodiqy Blood Glucose Test System is intended to be used for the quantitative measurement of glucose in capillary whole blood from the fingertip. It is intended for use by people with diabetes mellitus at home (Over -the-Counter) as an aid in monitoring the effectiveness of diabetes control program. The Prodigy blood glucose test system can also be used at clinical sites by nurses or professional people to test patient's glucose level in whole blood. It is not intended for the diagnosis of or screening for diabetes mellitus, and not intended for use on neonates.
The Prodigy meter is to be used with the Prodigy Blood Glucose Test Strip, and the Prodigy Glucose Control Solutions.
Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Carole Benson
Revision Sign-Off
Page 1 of -
Office of In Vitro Diagnostic Device Evaluation and Safety
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :